Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.63 |
| ▸ | CA2 | P00918 | 5/20 | 0.63 |
| ▸ | ACHE | P22303 | 5/20 | 0.63 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | TLR4 | O00206 | 1/20 | 0.53 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 2/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7591612 | 1.00 | CA1 (0.63) | CA1CA2ACHEHDAC8ALDH1A1 | |
| SCHEMBL9490334 | 0.89 | CA1 (0.73) | CA1CA2ACHEHDAC8ALDH1A1 | |
| SCHEMBL6135270 | 0.86 | CA1 (0.59) | CA1CA2ACHEHDAC8ALDH1A1 | |
| SCHEMBL5681755 | 0.84 | CA1 (0.56) | CA1CA2ACHEHDAC8ALDH1A1 | |
| SCHEMBL23938186 | 0.84 | CA1 (0.61) | CA1CA2ACHEHDAC8ALDH1A1 | |
| SCHEMBL30968514 | 0.84 | CA1 (0.61) | CA1CA2ACHEHDAC8ALDH1A1 | |
| SCHEMBL30061424 | 0.84 | CA1 (0.61) | CA1CA2ACHEHDAC8ALDH1A1 | |
| SCHEMBL17549529 | 0.84 | CA1 (0.61) | CA1CA2ACHEHDAC8ALDH1A1 | |
| SCHEMBL28576386 | 0.84 | CA1 (0.61) | CA1CA2ACHEHDAC8ALDH1A1 | |
| SCHEMBL30059982 | 0.84 | CA1 (0.61) | CA1CA2ACHEHDAC8ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030160-B2 | Propanolaminotetralines, preparation thereof and compositions containing same | SANOFI-AVENTIS (FR) | 2006-04-18 | — | — | US | disclosed |
| US-20040034070-A1 | Propanolaminotetralines, preparation thereof and compositions containing same | SANOFI-AVENTIS (FR) | 2004-02-19 | — | — | US | disclosed |
| CN-1100032-C | 3,4-disubstituted phenylethanolaminotetra lincarboxamide derivatives | KISSEI PHARMACEUTICAL (JP) | 2003-01-29 | — | — | CN | disclosed |
| EP-0882704-B1 | 3,4-DISUBSTITUTED PHENYLETHANOLAMINOTETRALINCARBOXAMIDE DERIVATIVES | KISSEI PHARMACEUTICAL (JP) | 2002-10-09 | — | — | EP | disclosed |
| US-6133266-A | 3,4-disubstituted phenylethanolaminotetralincarboxamide derivatives | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2000-10-17 | — | — | US | disclosed |
| CN-1216526-A | 3,4-disubstituted phenylethanolaminotetra lincarboxamide derivatives | KISSEI PHARMACEUTICAL (JP) | 1999-05-12 | — | — | CN | disclosed |
| EP-0882704-A1 | 3,4-DISUBSTITUTED PHENYLETHANOLAMINOTETRALINCARBOXAMIDE DERIVATIVES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034070-A1 | Propanolaminotetralines, preparation thereof and compositions containing same | ADRB3, ADRB1, ADRB2 | CA1 4712/4885CA2 3342/4885ACHE 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.